A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.

Daniel Morgensztern Neal E Ready Melissa Lynne Johnson Afshin Dowlati Noura J Choudhury David P Carbone Eric Schaefer Susanne M Arnold Sonam Puri Zofia Piotrowska Aparna Hegde Anne C Chiang Wade T Iams Anthony W Tolcher Kaname Nosaki Toshiyuki Kozuki Tianhong Li Rafael Santana-Davila Hiroaki Akamatsu Haruyasu Murakami Hiroshi Yokouchi Song Wang Jiuhong Zha Rui Li Randy R Robinson Pooja Hingorani Edwin E Jeng Muhammad Furqan

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

ABBV-011 1.0 mg/kg Q3W monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated patients with relapsed/refractory SCLC. SEZ6 is a promising novel SCLC target and warrants further investigation.

Keyphrases

small cell lung cancer
endothelial cells
cancer therapy
acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
randomized controlled trial
open label
pluripotent stem cells
induced pluripotent stem cells
brain metastases
clinical trial
amino acid